Genta Genasense Confirmatory Chronic Leukemia Trial To Begin By Year End
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Genta plans to launch a confirmatory trial of Genasense (oblimersen sodium) in chronic lymphocytic leukemia (CLL) before the end of 2005, the firm says.
You may also be interested in...
Time To Call It Quits: Genasense Failure Marks Its End And Leaves Genta On The Ropes Again
Genta ended a decade-long effort to validate the effectiveness of Genasense (oblimersen) with the May 23 announcement that the troubled antisense asset performed little better than chemotherapy alone in a targeted subset of patients with advanced melanoma.
Genasense chronic leukemia NDA gets rolling
Genta has initiated a rolling NDA for use of Genasense (oblimersen) in combination with fludarabine and cyclophosphamide in fludarabine-experienced chronic lymphocytic leukemia patients, the firm says June 30. Genta expects to complete the submission within six months. The company previously indicated it would initiate a confirmatory CLL study for accelerated approval before year-end (1Pharmaceutical Approvals Monthly June 2005, p. 3); the company says it "plans to discuss the design of that study with FDA." The CLL NDA will include a Phase I/II study of Genasense alone in relapsed/refractory CLL and a Phase III study of Genasense in combination with the flu/cy regimen versus fly/cy alone. The latter study showed a significant benefit for complete response, but Genta said overall survival "is too early to analyze"...
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011